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Abstract 
In this report we present a method to cultivate Borrelia spirochetes from human serum samples 
with high efficiency. This method incorporates improved sample collection, optimization of culture 
media and use of matrix protein. The method was first optimized utilizing Borrelia laboratory 
strains, and later by demonstrating growth of Borrelia from sera from fifty seropositive Lyme 
disease patients followed by another cohort of 72 Lyme disease patients, all of whom satisfied the 
strict CDC surveillance case definition for Lyme disease. The procedure resulted in positive 
cultures in 47% at 6 days and 94% at week 16. Negative controls included 48 cases. The positive 
identification of Borrelia was performed by immunostaining, PCR, and direct DNA sequencing. 
Key words: Clinical microbiology, Vector-borne diseases, Lyme disease, Spirochetes. 
Introduction 
It has long been an elusive goal to develop a 
successful in vitro culture method for wild-type, 
pathogenic Borrelia. Multiple attempts using a variety 
of methods have not been able to obtain a high yield 
or keep them alive for an extended period of time [1] 
[2]. A successful culture system would be highly 
useful, especially in light of the recognized public 
health impact of the pathogen Borrelia burgdorferi, the 
causative agent of Lyme disease. 
Lyme disease is a rapidly emerging infectious 
disease in the United States [3]. In most cases of Lyme 
disease, early detection and treatment with a course of 
antibiotics results in a successful outcome [2], [4]. 
However, because the signs and symptoms of dis-
seminated Lyme disease are shared with many other 
diseases [5], and because currently recommended 
diagnostic laboratory tests are not 100% sensitive, 
many cases of Lyme disease go undiagnosed and un-
treated, putting an infected patient at risk for devel-
oping a debilitating long-term illness [1] [6]-[9]. The 
current recommended standard for Lyme disease 
testing employs an indirect 2-step serological assay 
that detects host immune reactivity to the Lyme dis-
ease bacteria [1] [2] [5]. In a significant number of 
cases the serologic assays are not sufficiently sensitive 
or specific [1], [10]-[15] in part due to the presence of 
immune suppressive and modulating agents trans-
mitted by the tick and secreted by the Borrelia spiro-
chete [13]-[15] and antigen-antibody complex for-
mation [16]-[19]. Thus DNA-detection methods 
(polymerase chain reaction or PCR) have been de-
veloped but the assay has less than optimal sensitivity 
as the concentration of Borrelia spirochetes in blood, 
plasma, or serum samples from Lyme disease patients 
can be very low [1], [2], [20]-[23]. In addition, inhibi-
tors of PCR have been demonstrated to exist in the 
peripheral blood [24]. For technical reasons 
false-positive PCRs remain a concern [22], [25]. 
Therefore, there is a need to improve methods to de-
tect Borrelia infection in patients including methods to 
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cultivate Borrelia from human blood, urine, or tissue 
samples [26].  
The Borrelia-specific Barbour-Stoenner-Kelly 
media (BSK media) has been used to culture Borrelia 
[27], but the sensitivity is suboptimal [1], [2], [10], 
[28]-[30]. The reported sensitivities range from as low 
as 5% to a maximum of 88% in skin samples but a 
maximum of only 40-44% for peripheral blood sam-
ples [1], [10], [28]-[32]. Because of these difficulties, 
Borrelia cultures until now have not been widely used.  
We report an improved method to cultivate Bor-
relia from human blood samples with a success rate of 
94 %. This culture method incorporates two-step 
process that consists of a short-term starter culture 
that is used to seed a long-term phase, each utilizing 
different cultivation environments. Combining the 
two phases allows for more rapid initial growth and 
ultimately a higher yield than has previously been 
reported. This highly sensitive and specific method to 
detect live Borrelia cultivated from patient’s serum 
will improve our ability to make the diagnosis in cases 
in which serologic or PCR based assays are not in-
formative. In addition, cultures have been maintained 
for as long as eight months, offering the potential to 
serve as a useful source of clinical isolates for further 
study.  
Materials and Methods 
Abbreviations/nomenclature 
Members of the Borrelia genus often referred to 
as Borrelia burgdorferi sensu lato, Borrelia species, Borre-
lia spp, will be referred to in this study by the genus 
name, Borrelia. When species of Borrelia are referred to 
here, they will be indicated by the specific species 
name.  
Culture of established cell lines 
Low passage isolates of two different Borrelia 
burgdorferi strains, B31 (ATCC # 35210) and 297 
(ATCC # 53899), Borrelia afzelii (ATCC # 51992), and 
Borrelia garinii (ATCC # 51991) were obtained from 
American Type Tissue Collection. Escherichia coli 
DH5α strain was purchased from Life Technologies. 
Borrelia strains were maintained in complete BSK-H 
media, which includes 6% rabbit serum (complete 
media from Sigma-Aldrich #B8291) at 34oC with 5% 
CO2 and 100% humidity. Each new lot of complete 
BSK-H media was tested in a reference strain culture 
as a measure of quality assurance. Escherichia coli cells 
were maintained in standard Luria Broth media 
(Sigma) at 37oC in a shaking incubator. 
Blood collection 
Full informed consent was obtained from each 
study participant and HIPAA-compliant privacy 
measures were maintained. All patients who partici-
pated in this study had not been exposed to antibiotics 
for a minimum of 4 weeks prior to blood sample col-
lection [33] [34]. Sera from 50 seropositive patients 
were used to establish the culture media and condi-
tions. After the cultivation parameters were estab-
lished, sera from an additional 72 Lyme disease pa-
tients (26 males and 46 females ranging in age from 3 
to 80 years with average of 42 years) were collected 
between March 2011 and May 2012 and used to eval-
uate this culture method. All of these patients had a 
clinical presentation consistent with Lyme disease 
and their illness was confirmed by laboratory evi-
dence of infection using the Center for Disease Con-
trol (CDC) recommended, 2-tiered serological meth-
od, thus they all satisfied the strict CDC surveillance 
case definition for Lyme disease. 
To determine the specificity of the test we col-
lected serum from 48 healthy controls that had no 
history of either tick-bites or Lyme disease (21 males 
and 27 females ranging in age from 27 to 71 years with 
an average of 43 years). Patients and controls were 
selected from private medical practices from 15 dif-
ferent States (CA, AR, CT, NH, NJ, NY, MA, MD, MN, 
OR, PA, TN, UT, VT). Samples were delivered to the 
laboratory and cultures were initiated within 24-30 
hours of collection. 
Culture protocol 
Blood samples (~30 ml /patient) were collected 
in the following tubes: 9.0 ml peripheral blood in a 
15.0 ml polypropylene Falcon tube containing 5 ml 
BSK-H, two samples consisting of 9.0 ml peripheral 
blood in 10.0 ml red top (no additive) Vacutainer tube, 
or Vacutainer tubes containing EDTA (purple top). 
Blood samples were transported to the laboratory 
overnight at room temperature and upon receipt they 
were allowed to sit undisturbed for several hours at 
room temperature to allow serum separation. The 
serum was divided into eight starter cultures for each 
clinical sample and mixed with modified BSK-H me-
dia (mBSK-H) - four in the standard 15 ml glass tube 
(13 ml final volume) and four in the small 2ml cryo 
tubes (1.8 ml final volume) as summarized in Table 2. 
Cultures were incubated at 34º C with 5% CO2 and 
100% humidity. The lids of all culture tubes were 
closed loosely to allow limited gas exchange between 
the culture medium and the environment. Starter 
cultures were harvested after 6 days and used for ei-
ther immunocytochemical studies or to seed a 
long-term culture. Long-term cultures were estab-
lished by combining and directly transferring cells 
and media from culture tubes to a Coplin jar with an 
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additional 15 ml mBSK-H media (total volume of 34 
ml), a 5 µg rifampicin disc (BD Scientific) and 2 colla-
gen coated slides (Rat-tail type I; BD Scientific) and 
maintained through 16 weeks at 34oC with 5% CO2 
and 100% humidity. After 8 weeks, one slide was 
checked under dark field microscopy and used for 
polyclonal anti-Borrelia antibody detection analysis. If 
the fluorescent antibody result was negative at 8 
weeks of culture, another collagen coated slide was 
placed in the Coplin jar and half of the culture media 
(~17 ml) was replaced with fresh mBSK-H medium 
and the culture was incubated for an additional 8 
weeks. 
Immunodetection with polyclonal and mono-
clonal antibodies 
For detection of Borrelia using the polyclonal an-
tibody, cells from the starter culture tubes (Table 1) 
were centrifuged at 9,600xg for 10 minutes at room 
temperature, washed with 1x PBS buffer, pH 7.4, and 
centrifuged again at 9,600xg. The pellet was resus-
pended in 75 µl of 1x PBS buffer and spread on a mi-
croscope slide (SuperFrost+, Fischer Scientific). Cells 
were fixed by incubating the slides in acetone for 10 
minutes at -20 ºC. For collagen-coated slides, the cells 
were washed twice with 1x PBS, fixed in ice-cold ac-
etone:methanol (1:1) mixture for 10 minutes at -20 ºC, 
dried for 10 minutes at room temperature in a laminar 
air-flow hood, and further dried at 37º for 20 minutes. 
100 µl of polyclonal antibody (PA-1-73005 polyclonal 
FITC labeled anti-Borrelia burgdorferi antibody, 
Thermo Scientific, diluted 1:50 in 1% BSA/1x PBS) 
was added to the dried and fixed cells (300 µl for col-
lagen-coated slides). For a negative control, the pri-
mary antibody was omitted and replaced with normal 
rabbit serum. The slides were incubated at 37ºC in a 
humidified chamber for 1 hour, washed with 1x PBS 
for 5 minutes at room temperature, then rinsed twice 
in double distilled water and allowed to dry in the 
laminar air-flow hood for 10 minutes. The slides were 
mounted with Vectashield mounting medium with 
DAPI counterstain (Vector Labs) and images were 
taken by fluorescent microscopy. Unless noted oth-
erwise, microscopy was performed at 400x magnifi-
cation using an Olympus BX40 fluorescent micro-
scope with attached digital camera. An internal vali-
dation study for the specificity of the polyclonal an-
tibody showed that it is able to recognize reference 
cultures of Borrelia burgdorferi, Borrelia afzelii and Bor-
relia garinii, but not Escherichia coli or Treponema denti-
cola (data not shown).  
 
Table 1. Summary of the positive Borrelia clinical samples 
cultured in 15ml and 2ml tubes tubes/collection tubes. * 
positive samples grown in small tubes only. 
POSITIVE  
CULTURES 
CULTURE TUBES 
 15ml  2ml 
1 + - 
2 -  +* 
3 + - 
4 + - 
5 -  +* 
6 + - 
7 + + 
8 + + 
9 -  +* 
10 + + 
11 + - 
 12 + - 
13 + - 
14 + - 
15 + - 
16 + - 
17 + - 
18 + + 
19 -  +* 
20 + - 
21 -  +* 
22 + - 
23 + - 
24 + - 
25 + - 
26 + - 
27 + + 
Total 22 10 
 
Table 2. Description of the different culture environments 
for short-term cultures. * = modified BSK-H (including 12 % 
rabbit serum, 100 µg/ml of DTT and rifampicin as antibi-
otics). ICC=Immunocytochemistry, LTC=Long-term Cul-
ture. 
Tube
#  
Tube 
type 
Volume of the 
culture medium*  
Seed source Day 6 
use 
1 15 ml  11.0 ml  2.0 ml serum/BSK-H ICC 
2 15 ml  11.0 ml  2.0 ml serum/BSK-H LTC 
3 15 ml  11.5 ml  1.5 ml serum  LTC 
4 15 ml  11.5 ml  1.5 ml serum  ICC 
5 2 ml  1.4 ml  0.4 ml serum/BSK-H ICC 
6 2 ml  1.4 ml  0.4 ml serum/BSK-H LTC 
7 2 ml  1.6 ml  0.2 ml serum  LTC 
8 2 ml  1.6 ml  0.2 ml serum  ICC 
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For monoclonal antibody detection of Borrelia, 
cells were collected and adhered to a microscope slide 
as described for the polyclonal antibody protocol. The 
cells were fixed by incubation in fresh 4% paraform-
aldehyde solution for 20 minutes at room temperature 
followed by incubation in cold methanol for 20 
minutes at -20 ºC. The cells were treated in 0.3% Tri-
ton X-100 solution for 15 minutes at 37 ºC, then 
washed twice with 1x PBS, twice with double distilled 
water, air dried for 10 minutes in a laminar air-flow 
hood, and further dried at 37 ºC for 20 minutes. The 
slides were blocked with 100 µl diluted normal goat 
serum (5% in 1% BSA/1x PBS, Vector Labs) in a hu-
midified chamber at 37 ºC for 20 minutes. The slides 
were washed twice with 1x PBS, and twice with dou-
ble distilled water. 100 µl of monoclonal antibody 
(MA-1-7006, Thermo Scientific, raised against Bb, di-
luted 1:10 in 1% BSA/1x PBS) was added to each slide 
and incubated in a humidified chamber at room 
temperature overnight (~16h). For a negative control, 
the monoclonal antibody was omitted and replaced 
with normal mouse serum. The slides were washed 
twice with 1xPBS, and twice with distilled water. 100 
µl of goat anti-mouse secondary antibody (DyLight 
488 fluorescent dye labeled, diluted 1:200 in 1% 
BSA/1xPBS) was added to each slide and incubated 
in a humidified chamber at room temperature for 1 
hour under reduced light conditions. The slides were 
washed twice with 1x PBS, and twice with double 
distilled water and air dried in the dark under a lam-
inar flow hood for 15 minutes and counterstained 
with Vectashield with DAPI (Vector Labs). Images 
were acquired by fluorescent microscopy as described 
above. An internal validation study for the specificity 
of this monoclonal antibody showed that it is able to 
recognize Borrelia burgdorferi B31 and 297 strains but 
not the reference strains of Borrelia afzelii and Borrelia 
garinii, Escherichia coli or Treponema denticola (data not 
shown). 
DNA preparation from patient samples and 
cultures 
DNA was prepared from a portion of the initial 
patient serum sample; the remainder of the serum 
sample was used to seed the starter cultures. For 
analysis at short term, cells were collected immedi-
ately from serum (1-4 ml) by centrifugation at 9600xg 
for 10 minutes. For analysis at 8 or 16 weeks, cells 
were collected from the long-term culture media (10 
ml) or from the second collagen slide using a cell 
scraper in 1 ml of the culture media, by centrifugation 
at 9600xg for 10 minutes. DNA was extracted from 
cell pellets using the QiaAmp DNA extraction kit 
(Qiagen) according to the manufacturer’s instructions. 
Samples were eluted twice from the QiaAmp column 
with 50 µl QiaAmp elution buffer, pooled and stored 
at -20oC until analysis. 
PCR reactions 
Each positive culture sample was tested by PCR 
using primers designed to amplify Borrelia 16S ribo-
somal RNA small subunit or CTP synthase genes. The 
16S rRNA gene was amplified in a single reaction 
using primers F: 5’- CCTGGCTTAGAACTAACG-3’; 
R: 5’-CCTACAAAGCTTATTCCTCAT-3’ in a 50 µl 
reaction containing HotStarTaq buffer (Qiagen) 1.5 
mM MgCl2, 25 pmoles of each primer, and 2.5 units of 
HotStarTaq DNA polymerase (Qiagen). Reaction 
conditions were an initial denaturation at 94oC for 15 
minutes, followed by 40 cycles of 94oC/30s, 50oC/30s, 
72oC/1 min. then a final extension at 72oC/5min.  
CTP synthase sequences were amplified in 
nested reactions as described previously by Margos G 
et al [35]. First round primers were F: 
5’-ATTGCAAGTTCTGAGAATA-3’ and R: 
5’-CAAACATTACGAGCAAATTC-3’ in a 25 µl reac-
tion with HotStarTaq buffer (Qiagen), 25 pmoles of 
each primer, MgCl2 adjusted to 2.5 mM, and 1.5 units 
HotStarTaq. Reaction conditions were an initial de-
naturation at 94oC for 15 minutes, followed by 
94oC/30s, a 55oC step down from to 48oC decreasing 
1C per cycle, followed by 30 cycles of 94oC/30s, 
48oC/30s, 72oC/30s and a final extension at 
72oC/5min. The nested reaction primers were F: 5’- 
GATATGGAAAATATTTTATTTATTG -3’ and R: 
5’-AAACCAAGACAAATTCCAAG -3’ in a 50 µl re-
action containing 25 pmoles of each primer, 2.5 mM 
MgCl2, 1.5 units HotStarTaq. Reaction conditions 
were an initial denaturation at 94oC for 15 minutes, 
followed by 35 cycles of 94oC/30s, 50oC/30s, 
72oC/30s and a final extension at 72oC/5min. The 
PCR products were analyzed by standard agarose 
gel-electrophoresis. 
 
Sequencing and sequence analyses 
PCR products were purified using the QIAquick 
PCR purification kit (Qiagen) according to the manu-
facturer’s instructions. Samples were eluted twice in 
30 µl, and the eluates from each sample were pooled 
and sequenced in both directions using the primers 
that generated the products. Sequencing reactions 
were performed by Eurofins/MGW/Operon (Hunts-
ville, AL). Sequence alignment and neighbor-joining 
phylogenetic analyses were conducted using MEGA 
version 5 [36]. Tree support was evaluated by boot-
strapping with 500 replications. 
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Nucleotide sequence accession numbers 
Nucleotide sequences for CTP synthase locus for 
51 isolates have been deposited in GenBank 
(http://www.ncbi.nlm.nih.gov) with the following 
sequential accession numbers: JX867374 through 
JX867424. 
Statistical analyses 
Statistical analyses were performed using modi-
fied Wald method with a 95% confidence interval as 
well as the two-sample paired t-test utilized using 
NCSS statistical software (NCSS LLC, Kaysville, UT).  
Results 
Optimization of BSK-H media 
Standard BSK-H medium is the best available 
medium to cultivate Borrelia. We first attempted to 
improve the medium by testing a range of constitu-
ents including additional serum, reducing agents, and 
various antibiotics. Bb strains B31 and 297 were cul-
tured in BSK-H medium containing different amounts 
of rabbit serum (6%, 12% or 20%), and the culture was 
propagated at 34 °C with 5% CO2 and 100% humidity. 
The culture was examined for spirochete growth by 
dark field microscopy on day 6. While all three serum 
concentrations supported spirochete growth, cultur-
ing spirochetes in 12% rabbit serum yielded approx-
imately 25% more spirochetes for both strains (Figure 
1, Panel A, p=0.008).  
Dithiothreitol (DTT) is a reducing agent that has 
previously been found to improve the growth of Bor-
relia in vitro [37]. Bb B31 and 297 strains were cultured 
in BSK-H medium with 12% rabbit serum and either 
0. 145 µg/ml or 100 µg/ml DTT. The spirochete cul-
tures were incubated in a CO2 incubator at 34°C with 
5% CO2 and 100% humidity for 6 days. Compared to 
control or low dose DTT (0.145 µg/ml), 100 µg/ml of 
DTT nearly doubled the spirochete yield (p=0.0002) 
for both strains (Figure 1, Panel B).  
Antibiotics are commonly added to cultures to 
suppress the overgrowth of other organisms. To test 
the effect of this on Borrelia cultures, Bb B31 and 297 
strains were cultivated in BSK-H medium containing 
12% rabbit serum, 100 µg/ml DTT and one of the fol-
lowing antibiotics: 0.5 µg/ml rifampicin, a 5 µg ri-
fampicin disc (resulting in final concentration of 0.4 
µg/ml), 50 µg/ml rifampicin, or phosphomycin. The 
spirochetes were incubated in a CO2 incubator at 34°C 
with 5% CO2 and 100% humidity for 6 days and 
growth was evaluated by dark field microscopy. 
Culturing spirochetes with either 0.4 or 0.5 µg/ml 
rifampicin had no effect on spirochete yield, while 
using a higher concentration (50 µg/ml) of rifampicin 
significantly decreased the spirochete yield (Figure 1, 
Panel C, p=0.001). Similarly when three different 
concentrations of phosphomycin were included in the 
culture medium, spirochete yield was significantly 
reduced (data not shown). Therefore we did not in-
clude this antibiotic in subsequent experiments.  
 
Figure 1. shows the effect of different concentrations of rabbit serum (Panel A), DTT (Panel B) and antibiotic concentrations (Panel C) 
on the growth of Borrelia burgdorferi B31 strains. The cells were cultured for 6 days with different concentration of rabbit serum, DTT and 
antibiotics as depicted in the Figure and cellular growth was evaluated by direct cell counting of motile spirochetes using dark field 
microscopy. Each set of data represents three independent experiments (mean ± SD). Statistical significance was determined using 
two-sample paired t-test. The data *p-values <0.05 indicates statistical significance as related to control. 
Int. J. Med. Sci. 2013, Vol. 10 
 
 
http://www.medsci.org 
367 
Use of rifampicin alone (0.5 µg/ml or a 5 µg disc) 
in the culture prevented contamination in 120 of 122 
cases. Thus we utilized BSK-H medium with 12% 
normal rabbit serum, 100 µg/ml DTT, and either 0.4 
or 0.5 µg/ml rifampicin in our subsequent cultures 
and this will be referred to as modified BSK-H 
(mBSK-H) medium.  
Initial sample collection 
50 seropositive Lyme disease patients were 
studied to test variables in blood collection. Specifi-
cally, the use of plasma or serum from the peripheral 
blood with or without the addition of BSK-H media at 
the time of collection was examined. Peripheral blood 
samples were collected in purple-top Vacutainer 
tubes (EDTA additive, resulting in a plasma sample), 
in red-top Vacutainer tubes (no additive, resulting in a 
serum sample), and in 15 ml sterile Falcon tubes with 
5 ml of BSK-H medium and were shipped overnight 
to set up the culture. A positive culture was deter-
mined by dark field microscopy and immunocyto-
chemical methods. Collectively, 27 positive cultures 
were obtained from either the additive-free or BSK-H 
containing tubes. The tube with whole blood plus 
BSK-H medium provided the best environment for 
the 24h transit as this method produced the highest 
number of positive cultures (24/50, 48%). However, 
the additive-free tubes (serum) provided a sufficient 
transit environment for 11 samples (22%) with 8 sam-
ples growing from both tube formats (16%). Because 3 
cultures grew exclusively in the additive-free tube 
and to ensure no loss of spirochetes due to transport 
tube preference, further experiments utilized both 
transport systems. Blood collected in 
EDTA-containing tubes gave the lowest yield of 1/50 
and thus was abandoned from further use.  
Testing different culture tubes 
Most previous studies have cultured Borrelia in 
15 ml glass tubes which were tightly closed and 
placed in a standard 33-35 degree Celsius incubator 
[1], [27]. More recently, a smaller 2 ml polypropylene 
tube has been found to increase the yield [38]. There-
fore, the two different tubes were compared. Serum 
collected from 50 seropositive Lyme disease patients 
was inoculated into the two different tubes and cul-
tured with mBSK-H media. Cultures from 27 of these 
50 patients were positive for Borrelia by 6 days. Of the 
27 positive cultures, 5 were positive in both culture 
environments while 17 were positive in the 15 ml 
glass tube only, and 5 samples grew exclusively in the 
2 ml tube system as outlined in Table 1. Therefore, to 
maximize yield, both 15 ml and 2 ml tube formats 
were included in the final protocol. 
Figure 2 is a representative picture of three suc-
cessful cultures from seropositive Lyme disease pa-
tients after 6 days of culturing. PCR and direct se-
quencing of the 16S rDNA amplicon further con-
firmed the presence of Borrelia spirochetes.  
 
 
Figure 2. shows immunocytochemical images of representative cultures from three seropositive Lyme disease patients (Panel A, B and 
C). The serum samples were collected and cultured for 6 days and immunostained with polyclonal fluorescent antibodies against Borrelia 
burgdorferi as described in Materials and Methods. Magnification 400x. 
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Establishment of Long-term culture environ-
ment 
Each of the 50 cultures from seropositive Lyme 
patients described above was continued by adding 
fresh mBSK-H media and incubating them for addi-
tional time. However, after 8-10 days, further growth 
of the spiral form ceased and spirochetes tended to 
convert into different morphological forms (data not 
shown) as described previously [39]-[42]. Multiple 
attempts to revert them back to spiral form were un-
successful regardless of the use of several different 
media such as the original BSK-II medium [27], mod-
ified Kelly medium (MKP medium) [43], MPM me-
dium [44], and BSK modified medium [45]. In addi-
tion, several solid BSK-based media [46] and 
PMR-agar media [43] were similarly tested but like-
wise were not capable of maintaining spirochetal 
growth.  
We thus explored other variables: media and 
tubes (5-13 ml in 15 ml glass tubes and 1ml-1.8ml in 
the 2 ml small cryo tubes), other tube sizes (5ml and 
10ml tubes), tube material (glass and plastic), culture 
temperature (28-37 degree Celsius), CO2 concentra-
tion (0-5%), and O2 concentration using BD BBL 
Gaspak systems (anaerobic and semi-anaerobic sys-
tems). Despite altering these culture conditions, there 
was no improvement in growth.  
In summary, while the addition of serum, a re-
ducing agent and rifampicin had a positive effect on 
the short-term Borrelia cultures both by increasing 
yield and rate of initial growth, additional parameters 
needed to be optimized to improve long-term Borrelia 
cultures.  
In infected mammals, Borrelia are most often 
found to be sequestered in collagen and especially 
collagen type I [47] [48]. A collagen matrix has been 
shown to support growth of Borrelia burgdorferi B31 
and 297 strains in vitro [38] [49]. To study this further 
we initiated an experiment in which different 
amounts of Bb B31 cells (1, 10, 100, 1000) were spiked 
into 10 ml of whole peripheral blood from healthy 
donors and after a short term culture of 6 days in 
mBSK-H the culture was transferred to long-term 
cultures set up in Coplin jars with collagen-coated 
slides in a total of 45 ml of mBSK-H media. After 14 
days, an accumulation of Borrelia growth was ob-
served on all collagen coated slides. To evaluate this 
growth, a slide was removed from the Coplin jar and 
stained with the BacLight Live/Dead staining kit (see 
Materials and Methods). Figure 3A demonstrates a 
large thriving colony of attached spirochetes, with a 
very low proportion of non-viable spirochetes. Blood 
samples that were not spiked with Borrelia cells did 
not produce any spirochetes on the collagen-coated 
slides (Figure 3B). These data confirm that under fa-
vorable conditions human blood containing as few as 
one Borrelia B31 spirochete can be cultured in mBSK-H 
with a collagen source, which supports the original 
hypothesis that a matrix-supported environment is 
beneficial for their growth.  
 
 
Figure 3. shows BacLight DEAD/LIVE stained Borrelia burgdorferi on collagen-coated slides. For this experiment, 1 (Panel A) or 0 (Panel 
B) bacterial cell was spiked into 10 ml of human blood and cultured in a Coplin jar with collagen-coated slides and mBSK-H culture medium 
for 4 weeks and stained with Baclight DEAD/LIVE stains as described in Materials and Methods. Green staining=live cells, red stain-
ing=dead cells. Magnification: 200X.  
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Figure 4. shows the immunocytochemical images of one representative clinical sample of a Lyme disease patient whose diagnosis was 
supported by the 2-tiered serological method that follows the CDC surveillance testing guidelines. The serum sample was cultured with 
our culture method for 8 weeks and the obtained collagen-coated slides were immunostained with polyclonal fluorescent antibodies 
against Borrelia burgdorferi. Panels A-D represent 4 different fields of one collagen-coated slide showing individual spirochetes and small and 
large spirochetal aggregates that stained positively for Borrelia burgdorferi antigen (green staining). Magnification: 200X.  
 
To explore whether a collagen source would be 
beneficial to growth of wild type Borrelia, 10 cultures 
from serologically positive Lyme disease patients that 
were negative at day 6 in culture were converted into 
long-term cultures. After 4 and 8 weeks spirochetal 
growth was identified in four of these ten cultures and 
those spirochetal structures stained positively with 
the polyclonal anti-Borrelia antibody. Examination of 
the slides showed individual spirochetes as well as 
small and large aggregates of spirochetes. Figure 4 
shows representative fields of one collagen-coated 
slide from one of the positive samples (Panel A-D). To 
test whether a long-term culture can be set up direct-
ly, serum from seropositive Lyme disease patients 
was seeded into 45 ml of mBSK-H media in a Coplin 
jar containing two collagen slides. All attempts to es-
tablish a long-term Borrelia culture from patient sera 
in this manner were not successful (data not shown). 
This confirmed the need to seed a long-term culture 
from a short-term starter culture.  
Validation study in 72 CDC-positive Lyme 
disease patients 
This study enrolled 72 Lyme disease patients 
whose diagnosis was confirmed by a typical clinical 
history and a positive result on a 2-tiered serological 
test following CDC testing guidelines. It was required 
that each donor had not been exposed to antibiotics 
for a minimum of 4 weeks prior to blood draw as 
recommended in previous studies [33] [34]. 
Short-term cultures were established in mBSK-H as 
described and after six days these cultures were used 
to seed collagen-supported long-term cultures. The 
details of the procedure are summarized in Figure 5. 
Analysis on day 6 using polyclonal anti-Borrelia anti-
body revealed that 34 of the 72 (47%) cultures showed 
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growth (Figure 6). Long-term cultures were then be-
gun from all the patient samples at day 6 and were 
analyzed again at 8 and 16 weeks (Figure 6). An addi-
tional 26 samples became positive for Borrelia at 8 
weeks for a total of 60 of 72 (83%) and at 16 weeks an 
additional 8 samples became positive for Borrelia 68 of 
72 (94%). All samples that were positive by polyclonal 
staining (representative images in Figure 7) also 
stained positively with the monoclonal antibody 
(representative images in Figure 8).  
Borrelia-specific PCR products were amplified 
from each of the antibody-positive samples confirm-
ing that each sample contained Borrelia. Sequence 
analysis at the 16S rRNA or CTP synthase locus or 
both was performed and confirmed that each PCR 
product was Borrelia DNA. Significant sequence vari-
ations were identified among 51 samples sequenced at 
the CTP synthase gene locus indicating that samples 
were derived from independent sources and not from 
laboratory contamination. The percentage of the se-
quence identity of the clinical isolates to the Borrelia 
burgdorferi B31/N40 strains reference sequences (ac-
cession #AE000783 and #CP002228 respectively) 
ranged from 92%-100%. The numbers of polymorphic 
sites found in the clinical isolates for CTP synthase 
loci and the percentage of identity to Borrelia burgdor-
feri B31 sequence summarized in Table 3.  
 
Figure 5. outlines the individual steps of the short and long-term 
culture procedures. ICC=immunocytochemistry.  
 
 
 
Figure 6. summarizes the percentage of the successful Borrelia burgdorferi cultures of the clinical samples from the 72 Lyme disease 
patients whose diagnosis was supported by the 2-tiered serological method that follows the CDC surveillance testing guidelines. The 
samples were cultured with our novel method for 6 days, 8 weeks and 16 weeks and the cultures were confirmed to be Borrelia burgdorferi 
species by immunocytochemical and PCR methodologies (see Material and Methods). The figure shows that 34 of the 72 cultures were 
positive after 6-days of culturing (47% with a 95% confidence interval of 36%-58%) an additional 26 samples showed spirochetal presence 
at 8 weeks of culture (83% with a 95% confidence interval of 72%-92%). At 16 weeks an additional 8 samples became positive for spi-
rochetal growth (94% with a 95% confidence interval of 86%-97%). The confidence interval values are depicted by bars.  
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Figure 7. demonstrates immunocytochemical images of nine representative positive clinical samples of the 72 Lyme disease patients 
whose diagnosis was supported by the 2-tiered serological method that follows the CDC surveillance testing guidelines. The samples were 
cultured with our novel method for 8 weeks and immunostained with polyclonal fluorescent antibodies against Borrelia burgdorferi (green 
staining). Panels A-I: Nine representative samples, 400x.  
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Figure 8. demonstrates immunocytochemical images of nine representative clinical samples of 72 Lyme disease patients whose diagnosis 
was supported by the 2-tiered serological method that follows the CDC surveillance testing guidelines. The samples were cultured with 
our novel method for 8 weeks and immunostained with monoclonal fluorescent antibodies against Borrelia burgdorferi (green staining). 
Panels A-I: Nine representative samples, 400x.  
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Table 3. Summary of the numbers of the polymorphic sites for 
the CTP synthase locus and the % of identity to Borrelia burgdorferi 
B31 strain of the 51 clinical isolates obtained from our validation 
study. 
Number 
of Iso-
lates 
Genbank Accession Numbers of 
the Clinical Isolates 
# of Poly-
morphic 
Sites 
% of 
Identity 
to Borrelia 
burgdorferi 
B31 
10 JX867374, JX867377, JX867381 – 
92, JX867395 – 97, JX867399, 
JX867400 and JX867405 
0 100% 
1 JX867419 2 99% 
1 JX867376 21 97% 
1 JX867393 39 93% 
21 JX867375, JX867401 – 04, 
JX867406 – 16, JX867418 and 
JX867420 – 23 
41 93% 
4 JX867378 – JX867380 and 
JX867417 
42 93% 
1 JX867394 43 93% 
1 JX867398 49 92% 
1 JX867424 51 92% 
 
Sequence alignment (CLUSTELW) and neigh-
bor-joining phylogenetic analysis were conducted on 
a 600 bp alignment of the CTP synthase gene of Bb 
clinical isolates obtained from the validation study 
using MEGA 5 Evolutionary Genetics Analysis pro-
gram [36]. Tree support was evaluated by bootstrap-
ping with 500 replications. Figure 9 shows the result 
of the analyses indicating of several sequence clusters 
for the CTP synthase genes derived from the DNA 
samples of the 51 clinical isolates. The resulting CTP 
synthase sequences were submitted to the NCBI na-
tional genome database (accession numbers are listed 
in Materials and Methods). Limited sequence varia-
tion was also noted at the well-conserved 16S rDNA 
site (data not shown).  
To ensure the specificity of this culture method 
and any subsequent detection system, serum was 
collected from 48 healthy controls with no history of 
tick bites or of Lyme disease and was processed using 
the above short-term and long-term culture methods. 
All 48 negative control samples were negative by dark 
field microscopy and by anti-Borrelia monoclonal and 
polyclonal antibody staining at all time points we 
examined (6 days, 8 weeks, and 16 weeks; 100%).  
 
Figure 9. shows a neighbor-joining phylogenetic analysis of 600 bp 
alignment of the CTP synthase gene (pyrG) of the 51 Borrelia clinical 
isolates obtained from our validation study using MEGA 5 Evolu-
tionary Genetics Analysis program [36]. Alphanumeric codes rep-
resent GenBank (NCBI) ID numbers. Nucleotide sequences for CTP 
synthase locus for 51 clinical isolates have the following sequential 
accession numbers: JX867374 through JX867424. Numbers at nodes 
indicate bootstrap support values (500 replicates). 
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Discussion  
Here we report the development and evaluation 
of an improved method to culture Borrelia spirochetes 
from peripheral blood of confirmed Lyme disease 
patients. Results from this study showed that by op-
timizing collection and transport conditions, media 
and growth environment, and the development of a 
long-term culture method together provided im-
proved growth conditions for Borrelia. This is demon-
strated by a 94% detection rate for Borrelia burgdorferi 
from sera of Lyme disease patients whose diagnoses 
were confirmed under the CDC surveillance testing 
guidelines. We have also found significant sequence 
variation in these Borrelia samples which further 
documents that the Borrelia grown in this culture sys-
tem were not derived from laboratory contamination. 
The negative results from sera from healthy controls 
also argue against laboratory contamination as being 
the source of the positive cultures and further confirm 
the specificity of the test. 
The maximum success rate for Borrelia blood 
cultures as outlined in recent publications is in the 
40-44% range after 8-12 weeks of culturing [10] [30] 
[50]. By refining our collection and short-term culti-
vation methods we were able to get similar results 
after just six days in culture. The highest rate of Borre-
lia growth previously reported from clinical samples 
(up to 88%) involved cultures of skin, a tissue abun-
dant in collagen [1] [2]. Such studies revealed a 
maximal success rate similar to what we achieved in 
our long term, collagen supported in vitro culture 
system (84% at 8 weeks and 94% at 16 weeks).  
Unlike what has been reported by others, [50] we 
found poor results when blood specimens were col-
lected in tubes containing EDTA. We found that the 
addition of BSK-H medium to the whole blood sam-
ple at the time of collection increased spirochete yield. 
As previously reported [44], we also noted that al-
lowing the serum to separate, especially when mixed 
with BSK-H media, for up to 24 hours from the time of 
the blood draw improved the culture success rate. The 
BSK-H medium appeared to stabilize and even draw 
out the spirochetes from the cellular fraction. Presence 
of N-acetyl glucosamine (NAG) in the BSK-H medi-
um, a known chemoattractant for Borrelia [51], may 
facilitate this separation and support the spirochetes 
during transport. Presumably, these freely suspended 
Borrelia were better able to be cultivated. Interestingly, 
there was a subset of clinical samples that grew better 
in the collection tubes without additional BSK media. 
Because of this observation, we utilized both methods 
in our experiments to ensure maximal yield. 
BSK-H has been the preferred media for isolating 
and cultivating spirochetes from human clinical sam-
ples [1] [27]. We made four changes that include: 1. 
Higher concentration of rabbit serum (12% instead of 
6%) incorporating the observation that cultivation of 
other Borrelia strains such as Borrelia hermsii requires a 
higher percentage of serum [52]. 2. Based on the pre-
vious observation that DTT added to BSK-H media 
helped to isolate Borrelia spirochetes from Ixodes ticks 
[37], by testing different concentrations of DTT we 
determined that a high concentration of DTT (100 
µg/ml) enhanced the growth of Borrelia in our cul-
tures. 3. Since Borrelia species are known to be micro-
aerophilic, meaning that while some oxygen is needed 
for viability, high oxygen concentrations can be in-
hibitory [53], conditions that limit but not eliminate 
oxygen, such as partially shut lids, nearly full tubes 
and use of a CO2 incubator facilitated growth. 4. Low 
concentration of rifampicin (0.4-0.5 µg/ml) prevented 
secondary bacterial overgrowth in all but 2 out of 122 
cultures used in this study. In addition, the use of two 
different types and sizes of tubes in the starter culture 
improved outcome.  
The long-term culture system provided the 
greatest advantage in achieving a higher success rate. 
It was found that modified BSK-H media did not 
provide an efficient in vitro culture environment after 
8-10 days. We thus investigated whether matrix pro-
tein as a solid support may provide a desirable envi-
ronment for growth of Borrelia. [48]-[49]. Several ma-
trix proteins were tested such as fibronectin, laminin 
and hyaluronan, but collagen gave the best results, 
consistent with previously published data [38] [54]. 
Interestingly, collagen is present both in skin biopsies 
and in the novel long-term culture presented here and 
may be a common reason for their growth advantage 
over other cultures.  
The identity of the spirochetes was confirmed in 
all of the 68 culture-positive, CDC-positive patients 
enrolled in the validation study by staining positively 
with Bb-specific monoclonal and polyclonal im-
munostains. Additionally, further confirmation of the 
presence of Borrelia burgdorferi in these samples was 
accomplished by testing all clinical isolates with DNA 
PCR and then directly sequencing the DNA products. 
Again, in all cases, results were consistent with Borre-
lia burgdorferi. 
Several measures were employed to rule out the 
possibility of false positives. Blood from 48 negative 
controls was cultivated using the above established 
methods and none showed any growth. Meticulous 
DNA analyses of the positive cultures including the 
use of both negative and positive controls in each PCR 
reaction did not reveal any evidence for contamina-
tion. To confirm that Borrelia isolates that were cul-
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tured from the 72 CDC positive patients were unique 
and to further prove that the PCR products were not 
from an environmental contaminant, PCR products 
were directly sequenced at either the 16S rRNA or the 
CTP synthase locus or both. The results confirmed 
that the sequences from each positive culture sample 
were derived from Borrelia. Sequence analysis within 
the amplified region of 16S rRNA gene showed only 
limited variation that is likely due to the highly con-
served nature of 16S rRNA gene [55]. However, 
abundant sequence variations were noted at the CTP 
synthase locus from the positive cultures, indicating 
that the clinical isolates are unique and derived from 
wild-type Borrelia and not from a laboratory contam-
inant. The PCR and sequencing results were included 
in this study to further validate the polyclonal and 
monoclonal antibody assays used for the develop-
ment of this Borrelia culture.  
In summary, this report provides evidence for 
the value of a novel method for culturing Borrelia from 
human serum samples. The inclusion of key compo-
nents such as modified culture media plus a unique 
culture environment has resulted in an improvement 
in the ability to cultivate this organism. This new 
culture method directly addresses the issue of the low 
numbers of Borrelia in clinical samples by amplifying 
their quantity through long term culture in which 
Borrelia were able to thrive for as long as eight months 
(data not shown). The versatility of this method al-
lows for samples to be harvested from the culture at 
any point in time for further study, and it also serves 
as a source of Borrelia for a variety of direct detection 
techniques as well as for additional research. Finally, 
this unique culture method could play an important 
role in providing useful diagnostic information for 
select Lyme disease patients who might have tested 
negatively by other methods. 
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